Researchers from AstraZeneca, a pharmaceutical company in Sweden, grew human heart cells in the matrix of a whole rat heart to make the mini organ.
They delivered solutions that strip away cells from the rat heart while preserving the lining matrix of the whole heart to repopulate with human cells, researchers said.
The remaining 'scaffold' is the framework of the heart - consisting of collagen and other proteins.
The vessels were intact, the valves working and the four chamber structure of the heart was maintained, and the organ was then repopulated with human cells.
The miniature hearts will make it easier to test potential new drugs for safety and efficacy, researchers said.
The findings were presented at the American Heart Association's Basic Cardiovascular Sciences 2017 Scientific Sessions.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
